2026 Patent Cliff: $200 Billion at Stake as Eliquis and Januvia Face Paragraph IV Challenges
The 2026 Patent Cliff and the Pivotal Role of Paragraph IV Filings
The FDA's patent certification and suitability petition processes are key regulatory mechanisms that determine the market entry timing for generic drugs. Through Paragraph IV filings, generic manufacturers can challenge the validity or non-infringement of original patents, allowing them to submit ANDAs (Abbreviated New Drug Applications) before patent expiration. 2026 marks the beginning of a significant 'patent cliff,' with blockbuster drugs like Eliquis (apixaban, Bristol-Myers Squibb/Pfizer), Januvia (sitagliptin, Merck), Entresto (sacubitril/valsartan, Novartis), and Rexulti (brexpiprazole, Otsuka/Lundbeck) facing patent expirations. From 2026 to 2030, over $200 billion in global revenue will be exposed to generic and biosimilar competition.
Eliquis: Projected 98.6% Revenue Decline from $14.4 Billion
Eliquis (apixaban, a Factor Xa inhibitor), co-marketed by Bristol-Myers Squibb (BMY) and Pfizer (PFE), generated global revenue of $14.4 billion in 2025. The European patent expires in May 2026, and the key U.S. patent (US 7,338,953) expires on November 21, 2026. Based on the FDA Paragraph IV filing list, 25 ANDAs have been filed for apixaban 2.5mg/5mg tablets, and Accord Healthcare has already received FDA generic approval in July 2020. Eliquis revenue is projected to decline sharply to $205 million by 2031, representing a 98.6% decrease. BMS has adopted a strategy to fill the pipeline gap through acquisitions of Karuna Therapeutics ($14 billion) and RayzeBio ($4.1 billion).
Januvia and Janumet: Confirmed Simultaneous Generic Launch by 25 Companies
Merck's (MRK) diabetes drugs, Januvia (sitagliptin, a DPP-4 inhibitor, with $2.255 billion in sales in 2023) and Janumet (sitagliptin/metformin, with $1.433 billion in sales), will have a simultaneous launch by 25 generic companies, including Teva (TEVA) and Viatris (VTRS), in May and July 2026, following a 2020 patent settlement. Past experience shows that drug prices typically fall by more than 80% when four or more generic companies enter the market. Lyrica (pregabalin) saw a 98% price drop from $7 to $0.13.
Strengthened FTC and FDA Regulations and Changes in the Generic Market Structure
The FDA will require brand companies to demonstrate the validity of patents listed in the Orange Book starting in 2026, which is expected to reduce the 'patent thicket' strategy by 30-40%. The FTC challenged 200 Orange Book patents related to 17 drugs on May 17, 2025, and the FDA launched a pilot program for expedited review of domestically manufactured generics in October 2025. The U.S. generic market is expected to reach $131.2 billion in 2026, with Teva Pharmaceutical (TEVA), Sandoz (SDZ), Viatris (VTRS), Sun Pharmaceutical, and Dr. Reddy's (RDY) leading the market.
Suitability Petitions and the Beneficiaries in the Generic Sector
A suitability petition is a regulatory pathway that allows generic companies to launch generics with different formulations, dosages, or routes of administration than the original drug through an ANDA. The success rate of Paragraph IV litigation for generic companies has increased to 58% since 2020 (compared to 41% from 2003 to 2019), and the first ANDA filer receives 180 days of marketing exclusivity. This provides a first-mover advantage for large generic companies and, combined with the expiration of additional blockbuster patents such as Calquence (acalabrutinib, AstraZeneca, $0.8 billion in sales), Orkambi (lumacaftor/ivacaftor, Vertex, $1.0 billion), and Sprycel (dasatinib, BMS), is expected to act as a structural growth catalyst for the generic sector.
From 2026 to 2030, over $200 billion in global blockbuster revenue will be exposed to generic competition, with Eliquis alone projected to decline from $14.4 billion to $205 million, a 98.6% decrease. Januvia/Janumet ($3.7 billion) is confirmed for a simultaneous generic launch by 25 companies. BMS (BMY) has undertaken acquisitions of Karuna and RayzeBio, totaling $18.1 billion, to offset the Eliquis revenue decline, but analysts point to a $38 billion growth gap, the largest among its peers. From a generic sector perspective, Teva (TEVA), Viatris (VTRS), and Sandoz (SDZ) can maximize their first-mover advantage in the $131.2 billion U.S. market based on 180-day marketing exclusivity and a 58% success rate (an all-time high). The FTC's challenge of 200 Orange Book patents and the FDA's requirement for demonstrating patent validity are structurally lowering barriers to entry. The IRA (Inflation Reduction Act) stipulates that the maximum fair price for Eliquis under Medicare will be $231 for a 30-day supply starting in January 2026, which further pressures brand profitability.
Source: FDA Drug Approvals (rss)